Insight Molecular Diagnostics Inc. Announces Board and Officer Changes
Ticker: IMDX · Form: 8-K · Filed: Sep 19, 2025 · CIK: 1642380
Sentiment: neutral
Topics: corporate-governance, management-change
TL;DR
Insight Molecular Diagnostics (formerly Oncocyte) reshuffled its board and officers on Sept 16.
AI Summary
Insight Molecular Diagnostics Inc. announced on September 16, 2025, changes in its board and officer composition, including the election of new directors and appointments of certain officers. The company, formerly known as Oncocyte Corp, is based in Nashville, TN, and incorporated in California.
Why It Matters
Changes in board and officer positions can signal shifts in company strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing reports routine corporate governance changes and does not involve financial distress or significant operational shifts.
Key Players & Entities
- Insight Molecular Diagnostics Inc. (company) — Registrant
- Oncocyte Corp (company) — Former company name
- September 16, 2025 (date) — Date of earliest event reported
- California (jurisdiction) — State of incorporation
- Nashville, TN (location) — Business and mail address
FAQ
What specific roles were affected by the officer appointments?
The filing indicates appointments of 'certain officers' but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing states the election of directors but does not list their names in the provided text.
When did the company officially change its name from Oncocyte Corp to Insight Molecular Diagnostics Inc.?
The filing lists multiple name change dates for Oncocyte Corp, with the most recent being September 20, 2021.
What is the primary business of Insight Molecular Diagnostics Inc.?
The company is involved in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' as indicated by its SIC code.
Where is Insight Molecular Diagnostics Inc. headquartered?
The company's business and mail address is listed as 2 International Plaza Dr., Suite 510, Nashville, TN 37217.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 13.2 · Accepted 2025-09-19 16:05:48
Key Financial Figures
- $420,000 — ident and Chief Executive Officer, from $420,000 to $520,000 and (ii) Andrea James, the
- $520,000 — ief Executive Officer, from $420,000 to $520,000 and (ii) Andrea James, the Company's Ch
- $341,250 — Company's Chief Financial Officer, from $341,250 to $441,250. Each of the salary increas
- $441,250 — ief Financial Officer, from $341,250 to $441,250. Each of the salary increases is effect
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-25-014240.txt ( ) — 193KB
- imdx-20250916.xsd (EX-101.SCH) — 3KB
- imdx-20250916_lab.xml (EX-101.LAB) — 33KB
- imdx-20250916_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INSIGHT MOLECULAR DIAGNOSTICS INC. Date: September 19, 2025 By: /s/ Peter Hong Peter Hong Vice President, General Counsel